Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. 

PLoS ONE. 2016;11(6):e0150655. doi:10.1371/journal.pone.0150655

Despite effective treatment for recent hepatitis C (HCV) infection, side-effects and adherence concerns limit its use among people who inject drugs (PWID).

This study evaluated health-related quality of life (HRQoL) and social functioning following infection and during recent HCV treatment.

Conclusions:

Social functioning can predict recent HCV treatment uptake and SVR. Efforts to maximise social stability may improve treatment response. Pegylated-interferon treatment is associated with reduced HRQoL on-treatment in an already vulnerable population of PWID that would be better served by interferon-free regimens particularly in treated target at PWID to prevent transmission

  • Access full text (open access) here 

 

Latest research shows Australia on track to cure Hepatitis C

Kirby Institute/UNSW – 21 February 2017

More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby Institute at UNSW Sydney.